Neurodegenerative Diseases Drugs Market Poised to Reach US$ 85 Bn by 2032, Driven by Steady 5.5% CAGR - Persistence Market Research

The neurodegenerative diseases drugs market is entering a defining growth phase as demographic pressures, scientific breakthroughs, and policy shifts converge to reshape the global therapeutic landscape. Valued at US$ 58.4 billion in 2025, the market is projected to reach US$ 85.0 billion by 2032, expanding at a 5.5% CAGR during the forecast period. This steady growth reflects rising awareness around early diagnosis, the approval of new disease-modifying therapies, and increased investment in biomarker-driven precision medicine. As the prevalence of Alzheimer's, Parkinson's, multiple sclerosis (MS), and other neurodegenerative disorders accelerates, pharmaceutical companies are prioritizing innovative drug classes that target underlying biological mechanisms rather than merely treating surface-level symptoms.

Aging populations, particularly in high-income countries, remain a central driver of the expanding patient base. With more individuals living longer, degenerative conditions that were once rare are now widespread, creating urgent clinical and economic challenges. Multiple sclerosis continues to be the leading disease indication, supported by strong advocacy, robust funding, and a mature regulatory environment for novel drug approvals. North America stands as the leading regional market, propelled by accelerated regulatory pathways, widespread diagnostic capacity, and payer willingness to reimburse disease-modifying drugs. The ongoing push toward early intervention, coupled with rising investments in imaging and biomarker technologies, underscores a profound shift in how healthcare systems approach neurodegeneration.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35538

Key Highlights from the Report

• Shift from symptomatic treatment to targeted immunomodulation and biologics is a leading market trend.
• Rising healthcare expenditure and more favorable reimbursement frameworks are stimulating global market expansion.
• Development of therapies addressing non-motor symptoms in Parkinson's is creating new commercial pathways.
• Immunomodulators are expected to hold 43.5% market share in 2025 due to strong efficacy in immune-mediated disease pathways.
• Multiple sclerosis remains the dominant indication driven by funding support and early adoption of novel therapies.
• Growth in North America is strengthened by advanced diagnostic infrastructure enabling early-stage treatment eligibility.

Market Segmentation
By Drug Class

The neurodegenerative diseases drugs market is broadly segmented across multiple drug classes, each contributing distinct therapeutic benefits. Immunomodulators remain the largest segment, positioned to capture approximately 43.5% of the market share in 2025. Their dominance is tied to their proven ability to intervene directly in neuroinflammatory processes, which play a fundamental role in multiple sclerosis and related conditions. This class benefits from decades of regulatory confidence, validated biomarkers, and well-defined patient response metrics. Alongside immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and other therapies continue to evolve, addressing both disease pathophysiology and symptom management.

Dopamine agonists, in particular, are gaining momentum due to their role in managing early-stage Parkinson's disease. Their ability to delay the introduction of levodopa-while reducing long-term complications such as dyskinesias-makes them a favorable option among clinicians. Meanwhile, the continuous development of small molecules, regenerative therapies, and gene-based modalities is diversifying the market's competitive landscape and widening treatment choices for patients.

By Disease Indication

Disease indication segmentation highlights the varying levels of commercial maturity and clinical demand across neurodegenerative disorders. Multiple sclerosis (MS) represents the most dominant segment, expected to account for around 62.6% of the market share in 2025. Its prominence stems from a well-characterized autoimmune etiology and the availability of more than 20 globally approved Disease-Modifying Therapies (DMTs). MS remains one of the few neurodegenerative conditions where early diagnosis and intervention have consistently demonstrated measurable improvements in long-term outcomes.

Alzheimer's disease, though historically limited to symptomatic therapies, is experiencing renewed momentum following the approval and commercialization of disease-modifying anti-amyloid treatments. The large patient population-estimated to exceed seven million individuals in the U.S. alone-creates substantial demand for innovative solutions. Other indications such as Spinal Muscular Atrophy (SMA) and Parkinson's disease continue to gain research attention, benefiting from advancements in gene therapy, stem cell treatment, and personalized medicine platforms.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/neurodegenerative-disease-drugs-market.asp

Regional Insights
North America

North America dominates the global neurodegenerative diseases drugs market, securing approximately 51.8% of the total share in 2025. The region's leadership is supported by strong regulatory momentum, particularly the FDA's approval of innovative disease-modifying therapies such as Eisai and Biogen's Leqembi for early-stage Alzheimer's. The Centers for Medicare & Medicaid Services (CMS) has expanded reimbursement coverage, setting a precedent for broader payer support and enhancing treatment affordability. In the U.S., rapid adoption of advanced diagnostics-including PET scans, CSF assays, and blood-based biomarkers-has strengthened early detection rates. Canada, though slightly more conservative in reimbursement decisions, is also investing heavily in precision neurology and early-stage research collaborations.

Europe

Europe shows a more measured but methodical adoption pattern influenced by rigorous health technology assessments and cost-effectiveness requirements. Following the EMA's conditional approval of Leqembi in 2024, countries such as Germany and France have taken cautious steps in assessing clinical value relative to cost. Europe is rapidly building its Real-World Data infrastructure to support evidence-based decision-making, with initiatives like the European Platform for Neurodegenerative Diseases (EPND) streamlining data-sharing across the region. National investments in aging research, decentralized clinical trials, and biomarker innovation continue to enhance Europe's long-term market potential.

Asia Pacific

Asia Pacific is quickly emerging as a dynamic growth hotspot. Countries such as Japan, China, and South Korea are accelerating R&D, expanding regulatory flexibility, and strengthening domestic pharmaceutical capabilities. Japan has become a global leader in fast-track approvals for Alzheimer's drugs, with the PMDA integrating Leqembi into the National Health Insurance program to address the country's urgent dementia burden. China, under the Healthy China 2030 initiative, is prioritizing neurodegenerative drug discovery with initiatives like the global Phase 3 development of GV-971. South Korea's growing biotech ecosystem is enhancing development of peptide-based and precision neurology therapies, creating new avenues for regional market expansion.

Market Drivers

The market is propelled by a rising emphasis on early diagnosis and intervention. Early-stage treatment has become a clinical imperative as studies demonstrate the superior efficacy of disease-modifying therapies when administered before extensive neuronal damage occurs. The approvals of lecanemab and donanemab have intensified global interest in early Alzheimer's treatment, prompting healthcare facilities to invest in advanced diagnostics such as amyloid PET imaging and blood-based biomarkers. These diagnostic advancements not only extend the window of therapeutic eligibility but also strengthen payer confidence in long-term treatment outcomes. Additionally, demographic shifts, greater disease awareness, improved healthcare infrastructure, and expanding clinical research programs support consistent global market acceleration.

Market Restraints

Despite strong growth prospects, the neurodegenerative diseases drugs market faces notable barriers. Diagnostic access remains uneven, as many hospitals, especially in emerging markets, lack the infrastructure required for biomarker-based diagnosis. Even in the U.S., fewer than one-third of neurologists routinely order PET or CSF biomarker tests due to cost constraints, availability issues, and limited reimbursement. This diagnostic gap limits real-world adoption of advanced therapies. Another complicating factor is persistent reliance on symptomatic treatments such as levodopa or donepezil, which often overshadow investment in novel drugs due to their low cost and familiarity. Reimbursement challenges remain an ongoing obstacle, particularly in regions where health systems are hesitant to cover high-cost biologics without long-term cost-effectiveness data.

Market Opportunities

Opportunities in the neurodegenerative diseases drugs market are expanding through rapid advancements in regenerative medicine and stem cell therapy. Stem cell-based interventions offer potential for neuronal restoration, shifting therapeutic expectations from symptom relief to structural repair. Pharmaceutical companies are increasingly exploring combination approaches-pairing stem cell therapy, immunomodulators, and targeted biologics-to improve long-term efficacy. Early clinical successes, such as BlueRock Therapeutics' iPSC-derived therapy for Parkinson's disease, have accelerated investment enthusiasm. Additionally, gene therapy, antisense oligonucleotides, improved blood-brain barrier delivery systems, and precision-targeted immunotherapies are opening new commercial avenues across both rare and high-prevalence neurodegenerative disorders.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35538

Company Insights

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S
• Mitsubishi Tanabe Pharma Corporation
• Others

Market Segmentation

By Drug Class

Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others

By Disease Indication

Multiple Sclerosis
Parkinson's Disease
Alzheimer's Disease
Spinal Muscular Atrophy (SMA)
Others

By Route of Administration

Oral
Injection
Transdermal

By End-use

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Recent Developments

In July 2025, Klotho Neurosciences received FDA Orphan Drug Designation for KLTO-202, a novel secreted-Klotho promoter gene therapy designed for ALS, unlocking market exclusivity and financial incentives.

In March 2025, Alpha Cognition Inc. launched ZUNVEYL for mild to moderate Alzheimer's disease, aiming to enhance accessible treatment options for patients and caregivers.

Conclusion

The neurodegenerative diseases drugs market is in the midst of a significant transformation. With a projected value of US$ 85.0 billion by 2032, the market reflects growing momentum behind disease-modifying therapies, precision diagnostics, and regenerative medicine. Early diagnosis, increased investment, and strong regulatory engagement are reshaping how healthcare systems approach Alzheimer's, Parkinson's, MS, and other disorders. While reimbursement challenges and diagnostic disparities persist, ongoing innovation in immunomodulation, gene therapy, and stem cell treatment is unlocking unprecedented therapeutic possibilities. As the global burden of neurodegenerative diseases rises, this market is poised to remain one of the most critical and dynamic frontiers in modern neuroscience and pharmaceutical development.

Read More Related Reports:

Sterilization Services Market https://www.persistencemarketresearch.com/market-research/sterilization-services-market.asp
Nocturia Market https://www.persistencemarketresearch.com/market-research/nocturia-market.asp
Physician Scheduling Systems Market https://www.persistencemarketresearch.com/market-research/physician-scheduling-systems-market.asp
Cutaneous Mastocytosis Treatment Market https://www.persistencemarketresearch.com/market-research/cutaneous-mastocytosis-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.